Mechanism of allopurinol induced TPMT inhibition

Biochemical Pharmacology

Volumn 86, Issue 4, 2013, Pages 539-547

  Blaker, P A ^a   Arenas Hernandez, M ^a   Smith, M A ^a   Shobowale Bakre, E A ^a   Fairbanks, L ^a   Irving, P M ^a   Sanderson, J D ^a   Marinaki, A M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allopurinol; Hypermethylation; Inhibition; Mechanism; Thiopurine; Thiopurine S methyltransferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BALANCED SALT SOLUTION; MERCAPTOPURINE; OXIPURINOL; THIOPURINE METHYLTRANSFERASE; THIOXANTHINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; ENTERITIS; ENZYME INHIBITION; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; REDUCTION KINETICS;

EID: 84884909938     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.002     Document Type: Article

References (60)

1. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, doubleblind study. N Engl J Med 1980;302(18):981-7.
2. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin N Am 1989;18(1):57-71. (Pubitemid 19077648)
3. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin N Am 1999;28(2):297-321. (Pubitemid 29306481)
4. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25(1):330-3. (Pubitemid 28006261)
5. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000545.
6. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368(9544):1339-48. (Pubitemid 44528747)
7. Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM, et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 2009;36(1):89-95.
8. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 2004;43(1): 13-8. (Pubitemid 38088361)
9. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122(4): 904-15. (Pubitemid 34267273)
10. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12(6):429-36. (Pubitemid 34918619)
11. Blaker PA, Arenas-Hernandez M, Marinaki AM, Sanderson JD. The pharmacogenetic basis of individual variation in thiopurine metabolism. Personal Med 2012;9(7):707-25.
12. Neurath MF, Kiesslich R, Teichgraber U, Fischer C, Hofmann U, Eichelbaum M, et al. 6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenter Hepatol 2005;3(10):1007-14. (Pubitemid 41415749)
13. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61(15): 5810-6. (Pubitemid 32769099)
14. Coulthard SA, Hogarth LA, Little M, Matheson EC, Redfern CP, Minto L, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002;62(1):102-9. (Pubitemid 34680521)
15. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5): 571-607.
16. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a metaanalysis. Gastroenterology 2006;130(4):1047-53.
17. Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007;102(11):2488-94. (Pubitemid 47631795)
18. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118(4):705-13. (Pubitemid 30171620)
19. Hindorf U, Lyrenas E, Nilsson A, Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004;39(11):1105-12. (Pubitemid 39536400)
20. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by coprescription of allopurinol. J Crohn's Colitis 2012;6:905-12.
21. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48(5):642-6. (Pubitemid 32378583)
22. Van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012;35(10):1181-9.
23. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966;15(7):863-80.
24. Elion GB. The purine path to chemotherapy. Science 1989;244(4900):41-7. (Pubitemid 19130741)
25. Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993;342(8863):83-4. (Pubitemid 23192425)
26. Chocair PR, Duley JA, Cameron JS, Arap S, Ianhez L, Sabbaga E, et al. Does lowdose allopurinol, with azathioprine, cyclosporin and prednisolone, improve renal transplant immunosuppression? Adv Exp Med Biol 1994;370:205-8.
27. Chrzanowska M, Krzymanski M. Determination of 6-thioguanine and 6- methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther Drug Monit 1999;21(2):231-7. (Pubitemid 29168903)
28. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22(5):441-6. (Pubitemid 41248111)
29. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5(2):209-14. (Pubitemid 46216945)
30. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, et al. Longterm outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28(6):734-41.
31. Keuzenkamp-Jansen CW, Deabreu RA, Bokkerink JP, Lambooy MA, Trijbels JM. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 1996;18(2):145-50. (Pubitemid 26162176)
32. Simmonds HA, Duley JA, Davies PM. Analysis of purines and pyrimidines in blood, urine and other physiological fluids. New York, NY: Wiley-Liss; 1991. p. 397-424.
33. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005;11(7):826-33. (Pubitemid 40975585)
34. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44(3):551-5. (Pubitemid 28141350)
35. Smith M, Blaker P, Patel C, Marinaki A, Arenas M, Escuredo E, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013;67:161-9.
36. Seinen ML, de Boer NK, Smid K, van Asseldonk DP, Bouma G, van Bodegraven AA, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during lowdose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 2011;30(12):1085-90.
37. Seinen ML, van Asseldonk DP, de Boer NK, Losekoot N, Smid K, Mulder CJ, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohn's Colitis 2013.
38. Duley JA, Chocair PR, Florin TH. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 2005;22(11-12):1161-2. (Pubitemid 41779525)
39. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994;48(11):2135-8. (Pubitemid 24359621)
40. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62(4):464-75. (Pubitemid 27475231)
41. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39(4):456-9.
42. Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E. Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem 2004;50(2):438-41. (Pubitemid 38156388)
43. Bronk JR, Lister N, Shaw MI. Transport and metabolism of 6-thioguanine and 6- mercaptopurine in mouse small intestine. Clin Sci 1988;74(6):629-38.
44. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther 1999;291(2):870-4. (Pubitemid 29503564)
45. Rundles RW. Metabolic effects of allopurinol and allo-xanthine. Ann Rheum Dis 1966;25(6 Suppl.):615-20.
46. Weir E, Fisher JR. The effect of allopurinol on the excretion of oxypurines by the chick. Biochim Biophys Acta 1970;222(2):556-7.
47. Rashidi MR, Beedham C, Smith JS, Davaran S. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab Pharmacokinet 2007;22(4):299-306.
48. Rundles RW. Effects of allopurinol on 6-mercaptopurine therapy in neoplastic diseases. Ann Rheum Dis 1966;25(6 Suppl.):655-6.
49. Krenitsky TA, Neil SM, Elion GB, Hitchings GH. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 1972;150(2): 585-99.
50. Krenitsky TA, Elion GB, Strelitz RA, Hitchings GH. Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization. J Biol Chem 1967;242(11):2675-82.
51. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 2011;51(1):179-84.
52. Woodson LC, Weinshilboum RM. Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 1983;32(5): 819-26.
53. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85(3):323-33. (Pubitemid 8333694)
54. Lennard L, Hale JP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 1993;36(4):277-84. (Pubitemid 23303523)
55. Rowland K, Lennard L, Lilleyman JS. In vitro metabolism of 6-mercaptopurine by human liver cytosol. Xenobiotica 1999;29(6):615-28. (Pubitemid 29332746)
56. Endresen L, Lie SO, Storm-Mathisen I, Rugstad HE, Stokke O. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug. Ther Drug Monit 1990;12(3):227-34. (Pubitemid 20150886)
57. Spector T, Jones TE, Lafon SW, Nelson DJ, Berens RL, Marr JJ. Monophosphates of formycin B and allopurinol riboside. Interactions with leishmanial and mammalian succino-AMP synthetase and GMP reductase. Biochem Pharmacol 1984;33(10):1611-7.
58. Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicology In Vitro 2008;22(3):632-42.
59. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine- treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 2008;65(1): 69-77. (Pubitemid 350265173)
60. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B5801 and allopurinolinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19(9):704-9.